DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma.

"all raw data have been uploaded to sequence read archive (sra) bioproject: prjna947744."

"Declarations Ethics approval and consent to participateThe present investigation was conducted in accordance with the ethical standards and the Declaration of Helsinki and approved by The Affiliated People’s Hospital of Ningbo University (No. NBU-2022-025). Informed consent from the patients has been obtained. All animal studies were identified by the Ethics Committee of The Affiliated People’s Hospital of Ningbo University (No. 2022–11086). All methods were performed in accordance with the relevant guidelines and regulations. Consent for publicationInformed consent from the patients has been obtained. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This research was supported by Ningbo Natural Science Foundation (Project ID2023J387), Medical Science and Technology Project of Zhejiang Province (Grant No. 2024KY373, No. 2023KY303), Natural Science Foundation of Zhejiang Province (LQ20H160010), Medical Science and Technology Project of Zhejiang Province, China (2023RC270), Project of NINGBO Leading Medical & Health Discipline (Project Number: 2022-B19), and the Postdoctoral Fund of Yinzhou District, Ningbo, Zhejiang Province."